Skip to main content
. 2021 Sep 23;4(4):888–902. doi: 10.20517/cdr.2021.44

Figure 3.

Figure 3

Panobinostat alters expression of class II and IV HDACs. (A) Myeloma cells (RMPI-8226wt or v10r or and Kas6wt or v10r) were treated with various concentrations of vorinostat (50, 100, 500, 1000, and 5000 nM) or panobinostat (50, 100, 500, 1000, and 5000 nM) for 48 h, and cell viability was measured. Viability was normalized to control treated with vehicle. (B) RMPI-8226wt or v10r and Kas6wt or v10r were treated with 50nM vorinostat or panobinostat for 12 h before harvesting for total RNA, and mRNA expression of class II and IV HDACs was measured by RT-PCR. Individual HDAC expression in RMPI-8226 and Kas6 cells treated with vorinostat or panobinostat was normalized to that in respective RMPI-8226 and Kas6 cells treated with vehicle only. *P < 0.05. HDACs: Histone deacetylases.